http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-20150024-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a88d8527d6dd99bc71959eb18cb3dd9 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate | 2015-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07712adae0b88e09c9db32e40aab6d7 |
| publicationDate | 2016-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-20150024-A1 |
| titleOfInvention | Use of antagonists to the nuclear receptor alone or in combination as direct antiviral agents to inhibit Arenaviridae,Filoviridae ,Bunyaviridae, Flaviviridae and Rhabdoviridae which viruses cause VHF (viral haemorrhagic fever) |
| abstract | The present invention is directed to therapeutic use of antagonists of the mineralocorticoid/aldosterone receptor for their previously unappreciated, prophylactic and therapeutic properties in preventing damage to the endothelial barrier that causes loss of vascular integrity resultant from filoviral infection of a patient and the effect of the Ebola viral coat glycoproteins GP1/2 attaching to the aldosterone receptor and causing the loss of endothelial cell attachment leading to characteristic hemorrhaging which results in hypovolemic shock to the patient. The invention also relates to compositions that comprise antagonist of the mineralocorticoid/aldosterone receptor and an excipient. |
| priorityDate | 2014-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 759.